Active	Status	Sponsor type	Region	Phase	Filter
2 Active 4 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Grothey, Axel
NCT05733611: RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC	Active, not recruiting	2	4	NA	RP2, RP3, atezolizumab, bevacizumab	Replimune Inc., Roche Pharma AG	Refractory Metastatic Colorectal Cancer, pMMR, MSS	01/27	03/27
NCT05733598: Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Recruiting	2	30	US	RP2, Bevacizumab, Avastin, Atezolizumab, Tecentriq	Replimune Inc., Roche Pharma AG	Hepatocellular Carcinoma	12/27	07/28